Hims & Hers is facing battles on multiple fronts as it seeks to maintain its lucrative business in copycat weight loss drugs.

Hims & Hers on Saturday announced it would stop offering its copycat of the weight-loss pill Wegovy after threats of legal ...

By Michael Erman NEW YORK, Feb 19 (Reuters) - Online telehealth company Hims & Hers Health, seeking growth drivers as its ...

Hims & Hers said it would stop selling its new compounded semaglutide pill after "constructive conversations with ...

NEW YORK, Feb 6 (Reuters) - Hims & Hers sent a shockwave through the pharmaceutical industry on Thursday with its ...

Novo's lawsuit comes less than one week after Hims & Hers announced plans to sell a compounded version of Novo's weight-loss ...

A month after drugmaker Novo Nordisk launched its Wegovy pill, online health and wellness company Hims & Hers plans to undercut it with a compounded semaglutide pill offered at a lower price.

US telehealth group Hims & Hers has launched a cheaper version of Novo Nordisk’s Wegovy pill to retail at $49 per month, ...

The deal would ⁠give Hims & Hers a foothold in Australia and Japan while deepening its presence in ‌the United Kingdom, ...

SAN FRANCISCO--(BUSINESS WIRE)-- Hims & Hers Health, Inc. (HIMS), the leading health and wellness platform, today announced an expansion of its weight loss specialty by enabling providers to prescribe ...